Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
Net Loss : Recorded a net loss of $44.1 million for the fourth quarter. Cash Position : Ended the year with $316.2 million in cash, cash equivalents, and investments. Clinical Progress : Initiated and advanced multiple Phase 1 studies, including FT819 and FT825 / ONO-8250 CAR T-cell programs. Shares Outstanding : 98.6 million common shares and 2.8 million preferred shares as of December 31, 2023. Warning! GuruFocus has detected 6 Warning Signs with FATE. On February 26, 2024, Fate Therapeutics Inc ( NASDAQ:FATE ) released its 8-K filing , detailing its financial results for the fourth quarter and the full year ended December 31, 2023. The clinical-stage biopharmaceutical company, which specializes in programmed cellular immunotherapies for cancer and immune disorders, has reported significant progress in its clinical trials and maintains a strong cash position to support its operations. Company Overview Fate Therapeutics Inc is at the forefront of developing novel immun
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesGlobeNewswire
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingGlobeNewswire
- Fate Therapeutics: Looking For A Potential Turnaround In 2024 [Seeking Alpha]Seeking Alpha
FATE
Earnings
- 2/26/24 - Beat
FATE
Sec Filings
- 5/2/24 - Form 424B3
- 4/30/24 - Form EFFECT
- 4/26/24 - Form ARS
- FATE's page on the SEC website